Cerbios header

Cerbios header

X

[{"orgOrder":0,"company":"Wize Pharma","sponsor":"Bonus BioGroup","pharmaFlowCategory":"D","amount":"$7.4 million","upfrontCash":"Undisclosed","newsHeadline":"Wize Pharma Executes Agreements for Strategic Transaction with Bonus BioGroup","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase IV","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Wize Pharma"},{"orgOrder":0,"company":"Wize Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wize Pharma Completes Phase IV Study of LO2A for the Treatment of Dry Eye Syndrome in Patients with Sj\u00f6gren's Syndrome","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase IV","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Wize Pharma"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recent 24-Month Real-World PALADIN Data Demonstrate the Ability of ILUVIEN\u00ae to Significantly Reduce Treatment Burden in Patients with Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Alimera Sciences"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 4 PALADIN Study with ILUVIEN\u00c2\u00ae Published in Peer-Reviewed Journal Ophthalmology","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Alimera Sciences"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 4 PALADIN Study Confirms Positive Predictive Value of Corticosteroid Course Prior to ILUVIEN\u00c2\u00ae Use for IOP Outcomes","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Alimera Sciences"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Paladin Phase 4 Study Confirms ILUVIEN\u00ae Patients' Reduced Need for Multiple Treatments","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Alimera Sciences"}]

Find Ophthalmology Drugs in Phase IV Development

Filters

×

FILTER:

filter

Company

filter

Sponsor

filter

Country

filter

Product Type

filter

News Type

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

Alimera Sciences

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Paladin Phase 4 Study Confirms ILUVIEN® Patients' Reduced Need for Multiple Treatments

Details:

PALADIN phase 4 data demonstrate ILUVIEN (fluocinolone acetonide) patients experienced on average an increase in visual acuity, a significant decrease in retinal thickness and a predictable and manageable safety profile over 36 months.

Lead Product(s): Fluocinolone Acetonide

Therapeutic Area: Ophthalmology Product Name: Iluvien

Highest Development Status: Phase IV Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 06, 2022

ASK
US

Upload
your Pipeline Activity

Alimera Sciences

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Phase 4 PALADIN Study Confirms Positive Predictive Value of Corticosteroid Course Prior to ILUVIENÂ® Use for IOP Outcomes

Details:

Iluvien (fluocinolone acetonide intravitreal implant), is designed to release sub-microgram levels, a corticosteroid, for 36 months, to reduce recurrence of disease and number of treatments required, enabling patients to maintain vision longer with fewer injections.

Lead Product(s): Fluocinolone Acetonide

Therapeutic Area: Ophthalmology Product Name: Iluvien

Highest Development Status: Phase IV Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 12, 2022

ASK
US

Upload
your Pipeline Activity

Alimera Sciences

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Phase 4 PALADIN Study with ILUVIENÂ® Published in Peer-Reviewed Journal Ophthalmology

Details:

ILUVIEN (fluocinolone acetonide), sustained release intravitreal implant, demonstrated statistically significant improvements in best-corrected visual acuity, central subfield thickness, also resulted in a 70.5% reduction in treatment burden at 36 months in PALADIN Study.

Lead Product(s): Fluocinolone Acetonide

Therapeutic Area: Ophthalmology Product Name: Iluvien

Highest Development Status: Phase IV Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 23, 2022

ASK
US

Upload
your Pipeline Activity

Alimera Sciences

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Recent 24-Month Real-World PALADIN Data Demonstrate the Ability of ILUVIEN® to Significantly Reduce Treatment Burden in Patients with Diabetic Macular Edema

Details:

The real-world data from the Phase 4 PALADIN study show that patients receiving one or less total injections per year for their DME after the ILUVIEN injection increased three-fold from prior to the ILUVIEN injection.

Lead Product(s): Fluocinolone Acetonide

Therapeutic Area: Ophthalmology Product Name: Iluvien

Highest Development Status: Phase IV Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 13, 2021

ASK
US

Upload
your Pipeline Activity

Wize Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Wize Pharma Completes Phase IV Study of LO2A for the Treatment of Dry Eye Syndrome in Patients with Sjögren's Syndrome

Details:

The clinical trial is designed to demonstrate the clinical efficacy and safety of LO2A in DES patients with Sjögren's syndrome. Phase IV study aims at expanding LO2A's current approved status.

Lead Product(s): Sodium Hyaluronate

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Phase IV Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 07, 2020

ASK
US

Upload
your Pipeline Activity

Wize Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Wize Pharma Executes Agreements for Strategic Transaction with Bonus BioGroup

Details:

This agreement will advance Wize Pharma's ongoing clinical program for LO2A, currently in a Phase IV study for the treatment of dry eye syndrome in patients with Sjogren's.

Lead Product(s): Sodium Hyaluronate

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Phase IV Product Type: Small molecule

Partner/Sponsor/Collaborator: Bonus BioGroup

Deal Size: $7.4 million Upfront Cash: Undisclosed

Deal Type: Agreement January 16, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY